BRAF and neoplasm: When no targetable mutation is identified (NTRK, ALK, RET or BRAF) or the tumor is not sequenced, the antiangiogenic multi-targeted kinase inhibitors (aaMKIs) Sorafenib, Lenvatinib and Cabozantinib may be used.